SMAD5 and Alzheimer disease: Has-miR-27a-3p was reported as a candidate biomarker for Alzheimer disease (AD)43, and combines miR-23a to target SMAD5 and regulate cell apoptosis by the FasL-Fas pathway in human granulose44.